In Brief: Angeion
This article was originally published in The Gray Sheet
Executive Summary
Angeion: Company resumes U.S. clinical implants of its Sentinel series of implantable cardioverter defibrillators immediately following FDA sign-off on Jan. 26, the firm states. The company had temporarily suspended implants of the Sentinel series, including 2000, 2010, 2011 and 2012 models, in November 1997 following five incidents in which battery voltage depleted prematurely due to a defective capacitor ("The Gray Sheet" Nov. 17, I&W-3). To correct the problem, Angeion changed its manufacturing process to incorporate a new capacitor component, and the firm has modified the monitoring schedule for patients implanted with the ICDs. Angeion filed a premarket approval application for the devices in June 1997 that is currently under review ("The Gray Sheet" June 23, In Brief)...
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.